Molecular mechanisms of congenital hyperinsulinism due to autosomal dominant mutations in ABCC8.
Nessa A, Aziz QH, Thomas AM, Harmer SC, Tinker A, Hussain K.
Hum Mol Genet. 2015 Sep 15;24(18):5142-53. doi: 10.1093/hmg/ddv233. Epub 2015 Jun 19.
Hyperinsulinism of the newborn.
Glaser B.
Semin Perinatol. 2000 Apr;24(2):150-63. doi: 10.1053/sp.2000.6365.
Insights in congenital hyperinsulinism.
Hussain K.
Endocr Dev. 2007;11:106-121. doi: 10.1159/000111066.
Congenital hyperinsulinism: molecular basis of a heterogeneous disease.
Meissner T, Beinbrech B, Mayatepek E.
Hum Mutat. 1999;13(5):351-61. doi: 10.1002/(SICI)1098-1004(1999)13:5<351::AID-HUMU3>3.0.CO;2-R.
Computational Identification of Novel Kir6 Channel Inhibitors.
Chen X, Garon A, Wieder M, Houtman MJC, Zangerl-Plessl EM, Langer T, van der Heyden MAG, Stary-Weinzinger A.
Front Pharmacol. 2019 May 24;10:549. doi: 10.3389/fphar.2019.00549. eCollection 2019.
Continuous spectrum of glucose dysmetabolism due to the KCNJ11 gene mutation-Case reports and review of the literature.
He B, Li X, Zhou Z.
J Diabetes. 2021 Jan;13(1):19-32. doi: 10.1111/1753-0407.13114. Epub 2020 Oct 27.
An autosomal dominant form of familial persistent hyperinsulinemic hypoglycemia of infancy, not linked to the sulfonylurea receptor locus.
Kukuvitis A, Deal C, Arbour L, Polychronakos C.
J Clin Endocrinol Metab. 1997 Apr;82(4):1192-4. doi: 10.1210/jcem.82.4.3904.
[From gene to disease; neonatal diabetes mellitus and the KCNJ11 gene].
Slingerland AS, Bruining GJ.
Ned Tijdschr Geneeskd. 2005 Dec 3;149(49):2732-6.
Molecular mechanisms of neonatal hyperinsulinism.
Giurgea I, Bellanné-Chantelot C, Ribeiro M, Hubert L, Sempoux C, Robert JJ, Blankenstein O, Hussain K, Brunelle F, Nihoul-Fékété C, Rahier J, Jaubert F, de Lonlay P.
Horm Res. 2006;66(6):289-96. doi: 10.1159/000095938. Epub 2006 Sep 26.
